ClinicalTrials.gg
CompletedNCT02308020Updated Dec 19, 2020Results posted

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

A Phase 2 interventional study of Abemaciclib in Breast Cancer, Non-small Cell Lung Cancer and Melanoma, sponsored by Eli Lilly and Company. Completed at 44 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
162
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing abemaciclib in Breast Neoplasms — 22 open to participants now, 34 under way, 10 of them phase 3. abemaciclib · Breast Neoplasms.

Enrollment
22nd of 55
162 · median 120
Started
2015
with 1 other
Phase 2
27 of 55
12 open now
Registered
5th of 55
by date
Lead sponsor
17 of 55
Eli Lilly and Company

Among the 55 studies testing abemaciclib in Breast Neoplasms, this one is the 22nd largest by enrollment, is one of 2 that started in 2015, is one of 27 in phase 2, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

22 of the 55 studies testing abemaciclib in Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing abemaciclib in Breast Neoplasms, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.

03

Conditions studied

  • Breast Cancer
  • Non-small Cell Lung Cancer
  • Melanoma
  • Brain Metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have secondary to hormone receptor positive breast cancer, NSCLC, or melanoma.
  • Have either human epidermal growth factor receptor 2 positive (+) (Study Part A) or negative HER2- (Study Part B) breast cancer.
  • Participants in Study Part C must have HR+ breast cancer, NSCLC, or melanoma with brain lesions clinically indicated for surgical resection as well as consent to provide tissue for drug concentration determination after 5 to 14 days of study drug dosing.
  • Participants in Part D must have NSCLC of any subtype.
  • Participants in Part E must have melanoma of any subtype.
  • Participants in Part F must have HR+ breast cancer, NSCLC, or melanoma with .
  • For Parts A, B, D, and E: Must have at least 1 measurable brain lesion ≥10 millimeters (mm) in the longest diameter (LD).
  • For Part C (surgical): Have brain lesion(s) for which surgical resection is clinically indicated.
  • Have completed local therapy (surgical resection, whole-breast radiotherapy (WBRT), or SRS) ≥14 days prior to initiating abemaciclib and recovered from all acute effects.
  • If receiving concomitant , must be on a stable or decreasing dose for at least 7 days prior to the baseline Gd-MRI.
  • Have a performance status of ≥70.
  • Have a ≥12 weeks.
  • For HR+ breast cancer participants in part A, B, C, and F: If currently receiving endocrine therapy, a participant may continue to receive the same endocrine therapy provided that extracranial disease is stable for at least 3 months and central nervous system (CNS) disease progression has occurred while on this endocrine therapy. If these conditions are not met, participants must discontinue endocrine therapy prior to initiation of abemaciclib.
  • For HER2+ breast cancer participants in parts A, C, and F: participants may receive concurrent treatment (ongoing or initiated simultaneously with abemaciclib) with IV trastuzumab.
  • For NSCLC participants in parts C, D, and F: if currently receiving gemcitabine or pemetrexed (single-agent or in combination with another therapy), a participant may continue to receive 1 of these 2 therapies provided that extracranial disease is stable for at least 6 weeks and CNS disease progression has occurred while on this therapy.
  • Have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Require immediate local therapy, including but not limited to WBRT, SRS, or surgical resection, for treatment of .
  • Are taking concurrent enzyme-inducing antiepileptic drugs (EIAED).
  • Have evidence of significant (ie, symptomatic) intracranial hemorrhage.
  • For Parts A, B, C, D, E: Have evidence of . Note: discrete dural are permitted.
  • Have experienced >2 seizures within 4 weeks prior to study entry.
  • For Parts A, B, D, E, and F: Have previously received treatment with any cyclin dependent kinase 6 (CDK6) inhibitor. For Part C participants may have received prior palbociclib or ribociclib, but not abemaciclib treatment.
  • Have known to Gd-MRI.
  • Have a preexisting chronic condition resulting in persistent diarrhea.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Part A Abemaciclib: HR+, HER2+ Breast Cancer

    Abemaciclib 200 milligram (mg) was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or in combination with endocrine therapy (ET). Participants with hormone receptor positive (HR+), HER2+ breast cancer receiving concurrent trastuzumab, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Part B Abemaciclib: HR+, HER2- Breast Cancer

    Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants in combination with endocrine therapy (ET). Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Part C Abemaciclib: Surgical Resection

    Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+, HER2+ breast cancer, NSCLC, or melanoma with intracranial lesions for which surgical resection is clinically indicated receiving concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours for 5-14 days prior to surgical resection. Dosing may resume following wound healing on a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Part D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)

    Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants with NSCLC receiving concurrent gemcitabine or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Part E Abemaciclib: Melanoma

    Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

  • Experimental
    Part F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma

    Abemaciclib 200 mg was administered orally once every 12 hours on days 1-21 of a 21-day cycle when administered as a single agent or for participants with breast cancer in combination with endocrine therapy (ET). Participants with HR+ (either HER2+ or HER2-) breast cancer, NSCLC, or melanoma and leptomeningeal metastases received concurrent trastuzumab, gemcitabine, or pemetrexed, 150 mg abemaciclib was given orally once every 12 hours on days 1-21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.

    Drug: Abemaciclib

Interventions

  • Administered orally

    Also known as: LY2835219

This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)

    OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).

    Time frame: Baseline to Objective Disease Progression (Up to 36 Months)

Secondary outcomes

  1. Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)

    Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).

    Time frame: Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Up to 36 Months)

  2. Duration of CR or PR: Duration of Intracranial Response (DOIR)

    DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.

    Time frame: Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up to 36 Months)

  3. Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)

    Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.

    Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)

  4. Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)

    ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.

    Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)

  5. Overall Survival (OS)

    OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.

    Time frame: Baseline to the Date of Death from Any Cause (Up to 5 Years)

  6. Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)

    The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

    Time frame: Baseline to Disease Progression (Up to 36 Months)

  7. Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)

    Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

    Time frame: Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)

  8. Progression Free Survival (PFS) Bi-compartmental

    PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.

    Time frame: Baseline to Objective Disease Progression or Death from Any Cause (Up to 36 Months)

  9. Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale

    The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.

    Time frame: Baseline, Cycle 3 (Up to 63 Days)

  10. Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)

    A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.

    Time frame: Parts A, B, D, E, F, Cycle 3, Day 1: Predose; Part C, Cycle 4, Day 1: Predose

07

Results

Posted Dec 19, 2019

Participant flow

Participant flow — Overall Study
MilestonePart A Abemaciclib: Hormone Receptor (HR+) HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: Non-Small Cell Lung Cancer (NSCLC)Part E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or Melanoma
Started27589282317
Received at least one dose of study drug27589282317
Completed23386241912
Not completed4203445
Withdrew: Lost to follow-up170012
Withdrew: Sponsor decision080221
Withdrew: Withdrawal by subject353212

Outcome measures

PrimaryPercentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)

OIRR is the percentage of participants with a (CR) or (PR) based on the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) response criteria. CR is measurable target lesions, the disappearance of all central nervous system (CNS) target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum longest duration (LD) of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. Stable disease (SD) is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. Progressive disease (PD) is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 millimeter (mm).

Time frame:
Baseline to Objective Disease Progression (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Objective Intracranial Response Rate (OIRR)05.800
SecondaryPercentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)

Percentage of Participants with BOIR was categorized as CR, PR, SD, PD or NE, as defined by RANO-BM, from baseline until the earliest of objective progression according to brain metastases response criteria or start of new anticancer therapy. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. NE is absent (no abnormality; normal), or non-evaluable (NE).

Time frame:
Baseline to Earliest Objective Progression or Start of New Anticancer Therapy (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD), or Not Evaluable (NE): Best Overall Intracranial Response (BOIR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Partial Response05.800
Stable Disease52.265.443.531.8
Progressive Disease47.828.856.568.2
Not Evaluable0000
SecondaryDuration of CR or PR: Duration of Intracranial Response (DOIR)

DOIR is measured from the date of first evidence of a confirmed response (CR or PR), as defined by RANO-BM, to the date objective progression or death from any cause. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Participants who have neither progressed nor died were censored on the day of their last radiographic tumor assessment or on the date of response. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. DOIR was summarized using Kaplan-Meier estimates.

Time frame:
Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Up to 36 Months)
Reported as:
Median · Months
Duration of CR or PR: Duration of Intracranial Response (DOIR)
MonthsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Duration of CR or PR: Duration of Intracranial Response (DOIR)—8.8 (3.0 to 14.3)——
SecondaryPercentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)

Percentage of participants with BOIR of CR, PR, or SD: IDCR, as defined by RANO-BM is reported. CR is measurable target lesions, the disappearance of all central nervous system CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Nontarget lesions requires disappearance CNS non-target lesions and no new CNS lesions. SD is less than (\<)30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.

Time frame:
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Percentage of Participants With Best Overall Intracranial Response (BOIR) of CR, PR, or SD: Intracranial Disease Control Rate (IDCR)52.271.243.531.8
SecondaryPercentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)

ICBR is the percentage of participants with BOIR of CR, PR, or SD with duration of SD for at least 6 months, as defined by RANO-BM. CR is measurable target lesions, the disappearance of all CNS target lesions for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. PR is at least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. SD is \<30% decrease relative to baseline but \<20% increase in sum LD relative to nadir. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm.

Time frame:
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Percentage of Participants With BOIR of CR, PR, or SD With Duration of SD for at Least 6 Months: Intracranial Clinical Benefit Rate (ICBR)13.026.926.19.1
SecondaryOverall Survival (OS)

OS was measured from baseline to the date of death from any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for a particular analysis, OS was censored for that analysis at the date of last contact prior to the data inclusion cutoff date (contacts considered in the determination of last contact date include adverse event (AE) date, tumor assessment date, visit date, and last known alive date). OS was summarized using Kaplan-Meier estimates.

Time frame:
Baseline to the Date of Death from Any Cause (Up to 5 Years)
Reported as:
Median · months
Overall Survival (OS)
monthsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Overall Survival (OS)10.06 (4.21 to 14.30)13.38 (9.60 to 20.84)7.13 (3.65 to 9.37)2.93 (1.22 to 4.31)
SecondaryPercentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)

The percentage of participants with a best response of CR or PR objective response rate is complete response (CR) + partial response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1) guidelines. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

Time frame:
Baseline to Disease Progression (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Percentage of Participants With a Best Response of CR or PR: Extracranial Objective Response Rate (EORR)01.73.60
SecondaryPercentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)

Disease control rate (DCR) (CR+ PR+ SD) per RECIST v1.1. is defined as the percentage of participants with best overall response of CR, PR, or SD. CR is disappearance of all target and non-target lesions; PR is ≥30% decrease in sum of longest diameter of target lesions. PD is defined as at least a 20% increase in the sum LD of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) and the 20% increase must be at least one lesion must increase by an absolute value of ≥5 mm to be considered progression.

Time frame:
Baseline to Disease Progression or Start of New Anticancer Therapy (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)
percentage of participantsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Percentage of Participants With a Best Overall Response of CR, PR, or SD: Extracranial Disease Control Rate (EDCR)40.751.739.326.1
SecondaryProgression Free Survival (PFS) Bi-compartmental

PFS was measured from baseline to objective progression (intracranial or extracranial) as defined by (RANO-BM.) or death from any cause. Participants who have neither progressed nor died were censored at the day of their last radiographic tumor assessment. PD is greater than or equal to (≥) 20% increase in sum LD relative to nadir and a relative increase of 20%, ≥1 lesion must increase by absolute value of ≥5 mm. PFS was summarized using Kaplan-Meier estimates.

Time frame:
Baseline to Objective Disease Progression or Death from Any Cause (Up to 36 Months)
Reported as:
Median · Months
Progression Free Survival (PFS) Bi-compartmental
MonthsPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
Progression Free Survival (PFS) Bi-compartmental2.07 (1.35 to 3.32)4.41 (2.60 to 5.46)1.45 (1.35 to 2.76)1.22 (1.02 to 1.55)
SecondaryChange From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale

The MDASI-BT is an instrument to assess multi-symptoms in participants with brain tumor metastases (including those with brain metastases secondary to breast cancer). The MDASI-BT of participants with a change from baseline is reported as mean core symptoms, mean brain tumor symptoms, and symptom groupings (mean focal neurologic deficit, mean generalized/disease status symptoms, and mean gastrointestinal symptoms). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.

Time frame:
Baseline, Cycle 3 (Up to 63 Days)
Reported as:
Mean · units on a scale
Change From Baseline in Neurologic Symptoms on the MD Anderson Inventory-Brain Tumor (MDASI-BT) Subscale
units on a scalePart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart D Abemaciclib: NSCLCPart E Abemaciclib: Melanoma
mean core symptom severity-0.98 ± 0.86-0.17 ± 0.99-0.38 ± 1.19-0.53 ± 0.62
mean brain tumor symptom severity-0.47 ± 0.57-0.29 ± 1.05-0.10 ± 1.220.31 ± 1.11
mean focal neurologic deficit symptom severity-0.84 ± 0.92-0.36 ± 1.23-0.44 ± 0.580.54 ± 1.16
mean generalized disease status-0.47 ± 1.030 ± 1.390.28 ± 1.510.01 ± 0.89
mean gastrointestinal symptom-1.35 ± 2.110.40 ± 1.911.00 ± 1.460 ± 0.29
SecondaryPharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)

A PK plasma sample was taken prior to abemaciclib dose to analyze the minimum concentrations of abemaciclib and its metabolites (Cmin) - Individual Cmin values were averaged if there were 3 or more available data points, otherwise individual data are reported.

Time frame:
Parts A, B, D, E, F, Cycle 3, Day 1: Predose; Part C, Cycle 4, Day 1: Predose
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Pharmacokinetics (PK): Steady State Minimum Concentration (Cmin) of Abemaciclib and Its Metabolites LSN2839567 (M2), LSN3106726 (M20), and LSN3106729 (M18)
nanogram/milliliter (ng/mL)Part A 150 mg Abemaciclib: HR+, HER2+ Breast CancerPart B 200 mg Abemaciclib: HR+, HER2- Breast CancerPart C 200 mg Abemaciclib: Surgical ResectionPart D 200 mg Abemaciclib: NSCLCPart E 200 mg Abemaciclib: MelanomaPart F 200 mg Abemaciclib: HR+ Breast Cancer, NSCLC, Melanoma
Abemaciclib133 ± 13.4120 ± 186NA ± NA306 ± 33.5NA ± NA142 ± 80.0
LSN2839567 (M2)72.6 ± 8.2377.3 ± 121NA ± NA100 ± 77.5NA ± NA68.5 ± 150
LSN3106726 (M20)158 ± 25.0133 ± 160NA ± NA203 ± 43.3NA ± NA122 ± 137
LSN3106729 (M18)36.8 ± 39.342.4 ± 85.6NA ± NA28.9 ± 108NA ± NA27.0 ± 242

Adverse events

Collected over Up to 36 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Abemaciclib: HR+, HER2+ Breast Cancer23/27 (85.2%)6/27 (22.2%)23/27 (85.2%)
Part B Abemaciclib: HR+, HER2- Breast Cancer38/58 (65.5%)16/58 (27.6%)55/58 (94.8%)
Part C Abemaciclib: Surgical Resection6/9 (66.7%)3/9 (33.3%)8/9 (88.9%)
Part D Abemaciclib: NSCLC24/28 (85.7%)8/28 (28.6%)27/28 (96.4%)
Part E Abemaciclib: Melanoma19/23 (82.6%)4/23 (17.4%)16/23 (69.6%)
Part F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma12/17 (70.6%)7/17 (41.2%)16/17 (94.1%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma
SeizureNervous system disorders2/270/580/91/281/232/17
PancreatitisGastrointestinal disorders0/270/581/90/280/230/17
SepsisInfections and infestations0/271/581/90/280/230/17
HypokalaemiaMetabolism and nutrition disorders0/270/581/90/280/231/17
Lung infectionInfections and infestations0/271/580/93/280/231/17
DehydrationMetabolism and nutrition disorders0/270/580/90/282/231/17
DiarrhoeaGastrointestinal disorders2/272/580/90/280/230/17
AnaemiaBlood and lymphatic system disorders0/270/580/90/280/231/17
NauseaGastrointestinal disorders0/270/580/90/280/231/17
Upper gastrointestinal haemorrhageGastrointestinal disorders0/270/580/90/280/231/17
Most frequent other events
Showing 10 of 115
Most frequent other events
EventPart A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F: Abemaciclib HR+ Breast Cancer, NSCLC, or Melanoma
DiarrhoeaGastrointestinal disorders15/2745/584/915/285/236/17
Alanine aminotransferase increasedInvestigations3/274/586/92/282/232/17
FatigueGeneral disorders9/2728/582/911/284/239/17
NauseaGastrointestinal disorders9/2726/582/98/281/237/17
AnaemiaBlood and lymphatic system disorders3/2712/584/95/282/235/17
LeukopeniaBlood and lymphatic system disorders2/277/584/94/283/233/17
NeutropeniaBlood and lymphatic system disorders6/2717/584/97/285/232/17
ThrombocytopeniaBlood and lymphatic system disorders4/2711/584/98/283/233/17
HypocalcaemiaMetabolism and nutrition disorders2/270/584/90/280/233/17
VomitingGastrointestinal disorders7/2720/582/94/281/235/17

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Part A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaTotal
Mean49.9 ± 10.954.1 ± 10.557.0 ± 17.958.4 ± 10.955.1 ± 14.450.1 ± 12.354.0 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)Part A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaTotal
Female27578141114131
Male0111412331
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaTotal
Hispanic or Latino0300115
Not Hispanic or Latino21428202014125
Unknown or Not Reported613182232
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaTotal
American Indian or Alaska Native0000000
Asian1310005
Native Hawaiian or Other Pacific Islander0000000
Black or African American1401017
White17357202214115
More than one race1100002
Unknown or Not Reported715171233
Region of Enrollment
Region of Enrollment(Participants)Part A Abemaciclib: HR+, HER2+ Breast CancerPart B Abemaciclib: HR+, HER2- Breast CancerPart C Abemaciclib: Surgical ResectionPart D Abemaciclib: NSCLCPart E Abemaciclib: MelanomaPart F Abemaciclib: HR+ Breast Cancer, NSCLC, or MelanomaTotal
Canada0100023
Austria0100001
Belgium48033018
United States112471271071
Italy04029015
Israel1201116
Australia2212119
France714171232
Spain2201117
08

Study locations

44 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California - San Diego
    La Jolla, California 92037-0845, United States
  • Univ of California San Francisco
    San Francisco, California 94115, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916-2233, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • Kaiser Permanente Center for Health Research
    Honolulu, Hawaii 96819, United States
  • James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Washington University Medical Center
    Saint Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Providence Health and Services
    Portland, Oregon 97213, United States
  • SMO Sarah Cannon Research Inst.
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Newcastle, 2298, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Southport, 4215, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloongabba, 4102, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wien, 1090, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussel, 1000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleroi, 6000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leuven, 3000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liege, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Ottawa, K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille Cedex, 59020, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lyon Cedex 08, 69373, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris Cedex 05, 75248, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint-Brieuc, 22027, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toulouse cedex 9, 31059, France
  • Hadassah Medical Center - Ein Karem
    Jerusalem, 9112001, Israel
  • Sheba Medical Center
    Tel Hashomer, 5265601, Israel
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cona, 44124, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genova, 16132, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Padova, 35128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Roma, 00128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barcelona, 08035, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madrid, 28034, Spain
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sevilla, 41013, Spain
09

References and documents

Publications

  • Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, Yardley D, Chan A, Conte P, Dieras V, Lin NU, Bear M, Chapman SC, Yang Z, Chen Y, Anders CK. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer. Clin Cancer Res. 2020 Oct 15;26(20):5310-5319. doi: 10.1158/1078-0432.CCR-20-1764. Epub 2020 Jul 21. Erratum In: Clin Cancer Res. 2021 Mar 1;27(5):1582. doi: 10.1158/1078-0432.CCR-21-0193. PubMed 32694159 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Nov 2018, 42 months.

Results were first posted in Dec 2019, 1 year 1 month after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 42 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2014
First posted
Dec 4, 2014
StartActual
Apr 20, 2015
Primary completionActual
Nov 8, 2018
CompletionActual
Nov 8, 2019
Results first posted
Dec 19, 2019
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02308020
Responsible party
Sponsor
First posted
Dec 4, 2014
Start date
Apr 20, 2015
Primary completion
Nov 8, 2018
Completion
Nov 8, 2019
Results posted
Dec 19, 2019
Last update
Dec 19, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-459) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion